XORTX THERAPEUTICS
XORTX Therapeutics is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease with secondary programs focused on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. At XORTX Therapeutics, they are dedicated to developing medications to improve the quality of life and future health of patients.
XORTX THERAPEUTICS
Industry:
Biopharma Biotechnology Pharmaceutical Therapeutics
Address:
Calgary, Alberta, Canada
Country:
Canada
Website Url:
http://www.xortx.com
Total Employee:
1+
Status:
Active
Contact:
+1 747 203 5240
Email Addresses:
[email protected]
Total Funding:
1000 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Domain Not Resolving Apache Euro Microsoft Exchange Online
Current Employees Featured
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-02 | XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study |
Official Site Inspections
http://www.xortx.com Semrush global rank: 3.73 M Semrush visits lastest month: 3.67 K
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Xortx Therapeutics"
Xortx Therapeutics - Crunchbase Company Profile
XORTX Therapeutics is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead …See details»
XORTX Therapeutics Inc. - Canadian Securities Exchange
Sep 30, 2015 XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney …See details»
XORTX Therapeutics Inc. - LinkedIn
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop …See details»
Xortx Therapeutics
Feb 25, 2025 In October 2010, Xortx licensed an exclusive North American patent portfolio related to GlycoMar Technology from the University of British Columbia. In 2014, the GlycoMar …See details»
XORTX Company Profile - Office Locations, Competitors, Revenue …
Nov 10, 2021 XORTX. Stock Price. $3.9. 2021-11-10. Market Capitalization. $528.4 M. 2021-11-10. XORTX Summary. Company Summary. Overview. XORTX Therapeutics is a drug …See details»
XORTX Therapeutics (TSXV:XRTX) Company Profile & Description
Mar 28, 2025 XORTX Therapeutics Company Description XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of …See details»
XORTX Therapeutics Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for XORTX Therapeutics Inc of Calgary, AB. Get the latest business insights from Dun & Bradstreet.See details»
XORTX Therapeutics - Overview, News & Similar companies
May 17, 2024 XORTX Therapeutics is a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney disea ses, …See details»
XORTX Provides Corporate Update
Jan 31, 2022 XORTX common shares commenced trading on the TSX Venture Exchange under the symbol XRTX and its common shares ceased trading on the Canadian Securities …See details»
About :: XORTX Therapeutics Inc. (XRTX)
XORTX is a drug-based biotechnology company focused primarily on diseases which involve aberrant purine metabolism and frequently high serum uric acid imbalance. Our focus on …See details»
XORTX Provides Update on FDA Type B Meeting Request
3 days ago For more information, please contact: Allen Davidoff, CEO: Nick Rigopulos, Director of Communications: [email protected] or +1 403 455 7727: [email protected] or …See details»
XORTX Highlights Pioneering Research Indicating a Role for …
Aug 29, 2024 Commenting on the research, Allen Davidoff, Ph.D., CEO of XORTX, stated, “The combination of pioneering research in autosomal dominant polycystic kidney disease …See details»
XORTX Therapeutics Inc. (XRTX) - Yahoo Finance
Find the latest XORTX Therapeutics Inc. (XRTX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical …
CALGARY, Alberta, Dec. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical …See details»
XORTX Therapeutics (XRTX) Stock Price & Overview - Stock Analysis
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. …See details»
XORTX Provides Update on FDA Type B Meeting Request - The …
3 days ago XORTX Provides Update on FDA Type B Meeting Request XORTX will focus on key steps . April 30, 2025. April 30, 2025. 5 min read. Save. New subscriber benefit!See details»
Press Releases :: XORTX Therapeutics Inc. (XRTX)
Dec 12, 2024 XORTX Announces Presentation at the Rare and Genetic Disease Summit . Oct 24, 2024 7:00am EDT. XORTX Sponsored Study Presented at the American Society of …See details»
XORTX Therapeutics (TSXV:XRTX) Stock Price & Overview
2 days ago XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney …See details»
XRTX Stock Price Quote | Morningstar
Apr 25, 2025 XORTX Commences Gout Program NDA Discussions with the FDA. GlobeNewswire Feb 24, 2025 12:00pm. XORTX to Present at Microcap Conference. …See details»
XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. …See details»